Analysts Are Bullish on These Consumer Goods Stocks: Sonae SGPS (GB:0ML0), Tate & Lyle (GB:TATE)
There's a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Sonae SGPS (GB:0ML0 – Research Report) and Tate & Lyle (GB:TATE – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Sonae SGPS (GB:0ML0)
In a report issued on May 22, Julian Megias from Kepler Capital maintained a Buy rating on Sonae SGPS, with a price target of EUR1.50. The company's shares closed last Friday at EUR1.25.
Megias has an average return of 19.1% when recommending Sonae SGPS.
According to TipRanks.com, Megias is ranked #4884 out of 9562 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonae SGPS with an EUR1.50 average price target.
Tate & Lyle (GB:TATE)
In a report issued on May 22, Karel Zoete from Kepler Capital maintained a Buy rating on Tate & Lyle, with a price target of p880.00. The company's shares closed last Friday at p545.00, close to its 52-week low of p507.00.
According to TipRanks.com, Zoete is ranked #7717 out of 9562 analysts.
Tate & Lyle has an analyst consensus of Strong Buy, with a price target consensus of p772.50, which is a 37.0% upside from current levels. In a report issued on May 16, Citi also upgraded the stock to Buy with a £6.70 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Kepler Capital Keeps Their Buy Rating on Waga Energy SA (WAGA)
In a report released on June 6, Baptiste de Leudeville from Kepler Capital maintained a Buy rating on Waga Energy SA (WAGA – Research Report), with a price target of €25.00. The company's shares closed last Friday at €23.05. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, de Leudeville is a 3-star analyst with an average return of 1.7% and a 45.19% success rate. de Leudeville covers the Industrials sector, focusing on stocks such as Waga Energy SA, Chargeurs SA, and Figeac Aero SA. Currently, the analyst consensus on Waga Energy SA is a Moderate Buy with an average price target of €25.00.
Business Insider
3 hours ago
- Business Insider
DHL Group (0H3Q) Receives a Buy from Kepler Capital
Kepler Capital analyst Marc Zeck maintained a Buy rating on DHL Group (0H3Q – Research Report) on June 6 and set a price target of €48.00. The company's shares closed last Friday at €40.71. Confident Investing Starts Here: Zeck covers the Industrials sector, focusing on stocks such as DHL Group, Kuehne + Nagel International AG, and DSV A/S. According to TipRanks, Zeck has an average return of 14.4% and a 71.43% success rate on recommended stocks. DHL Group has an analyst consensus of Moderate Buy, with a price target consensus of €45.46, an 11.68% upside from current levels. In a report released on June 3, Citi also upgraded the stock to a Buy with a €48.00 price target. Based on DHL Group's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of €20.81 billion and a net profit of €786 million. In comparison, last year the company earned a revenue of €20.25 billion and had a net profit of €743 million Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0H3Q in relation to earlier this year.
Business Insider
12 hours ago
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: Quince Therapeutics (QNCX) In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17. According to McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target. Moderna (MRNA) In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46. According to Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc. Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
